Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells
Author(s) -
Nayara C. Leite,
Elad Sintov,
Torsten Meißner,
Michael A. Brehm,
Dale L. Greiner,
David M. Harlan,
Douglas A. Melton
Publication year - 2020
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2020.107894
Subject(s) - induced pluripotent stem cell , immune system , stem cell , immunology , biology , in vitro , cell type , microbiology and biotechnology , medicine , cell , embryonic stem cell , genetics , gene
Understanding the root causes of autoimmune diseases is hampered by the inability to access relevant human tissues and identify the time of disease onset. To examine the interaction of immune cells and their cellular targets in type 1 diabetes, we differentiated human induced pluripotent stem cells into pancreatic endocrine cells, including β cells. Here, we describe an in vitro platform that models features of human type 1 diabetes using stress-induced patient-derived endocrine cells and autologous immune cells. We demonstrate a cell-type-specific response by autologous immune cells against induced pluripotent stem cell-derived β cells, along with a reduced effect on α cells. This approach represents a path to developing disease models that use patient-derived cells to predict the outcome of an autoimmune response.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom